Intravitreal pegaptanib as adjunctive treatment for stage 3+ ROP shown to be effective in a prospective, randomized, controlled multicenter clinical trial.

Abstract

PURPOSE:

Both intravitreal pegaptanib with laser therapy and intravitreal bevacizumab monotherapy have been found to be more efficacious than laser therapy alone in prospective, randomized, controlled clinical trials.

RESULTS:

The use of pegaptanib with laser therapy was efficacious in 91.2% compared with 69.0% in controls. The use of bevacizumab monotherapy was efficacious in 95.7% compared with 78.1% in controls.

CONCLUSIONS:

The use of anti-vascular endothelial growth factor therapy for retinopathy of prematurity has been shown to be efficacious, without toxicity reported to date; however, the best drug and dose which allows greatest efficacy with fewest recurrences and without toxicity must be determined.

• Authors: Helen A Mintz-Hittner
• Journal: European journal of ophthalmology (Eur J Ophthalmol) 2012 Sep-Oct Vol. 22 Issue 5 Pg. 685-6 ISSN: 1724-6016 [Electronic] United States
• PMID: 22669847 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)

Chemical References

• Angiogenesis Inhibitors
• Aptamers, Nucleotide
• VEGFA protein, human
• Vascular Endothelial Growth Factor A
• pegaptanib

Topics

• Angiogenesis Inhibitors (administration & dosage)
• Aptamers, Nucleotide (administration & dosage)
• Combined Modality Therapy
• Humans
• Infant, Newborn
• Intravitreal Injections
• Laser Coagulation
• Lasers, Semiconductor (therapeutic use)
• Prospective Studies
• Retinopathy of Prematurity (classification, drug therapy, surgery, therapy)
• Vascular Endothelial Growth Factor A (antagonists & inhibitors)